Thanks to all who participated in our September 15, 2020 webinar, “COVID-Associated Coagulopathy: A Conversation about the Controversies & Confusion” [click] featuring Dr. Andrew Goodwin, University of Vermont Medical Center. Click the title line if you would like to view the webinar again or if you did not have the opportunity to attend the live presentation. There is a lively Q&A session at the end. We’ll post some questions and responses here beginning with…
A question from Joan Polancic, MSED, MLS, Director, School of Medical Laboratory Science, Denver Health Medical Center:
Are there recommendations to screen all hospitalized COVID patients for coagulopathy? If so, do we use just the D-dimer to screen and then other tests if it is abnormal?
With the caveat that testing an unselected population without indications leads to numerous false positives in ratio to true positives, the D-dimer is being used early in all COVID patients not for diagnosis, but in order to follow disease progression from onset to recovery. D-dimer becomes elevated in all forms of acute inflammation. Typically the D-dimer is part of a profile that includes the PT, PTT, fibrinogen, and platelet count.
We solicit responses from our participants as we continue to explore the developing science surrounding the SARS-CoV-2 virus.